NCT07299617

Brief Summary

This randomized controlled study aims to determine the effect of pure lavender oil inhalation on headache severity and anxiety levels in hemodialysis (HD) patients. The research, conducted in three dialysis centers, included a total of 62 patients who were randomly assigned to either an intervention group (n=30) receiving lavender oil inhalation or a control group (n=32) receiving standard care. Data were collected using the Visual Analogue Scale (VAS) for headache severity and the State-Trait Anxiety Inventory (STAI) for anxiety levels.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
62

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2018

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2019

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2019

Completed
6.1 years until next milestone

First Submitted

Initial submission to the registry

September 22, 2025

Completed
3 months until next milestone

First Posted

Study publicly available on registry

December 23, 2025

Completed
Last Updated

December 23, 2025

Status Verified

December 1, 2025

Enrollment Period

2 months

First QC Date

September 22, 2025

Last Update Submit

December 20, 2025

Conditions

Keywords

HemodialysisPainAnxietyLavender oilNursing

Outcome Measures

Primary Outcomes (1)

  • Headache Severity measured by Visual Analog Scale (VAS).

    Headache severity is measured using a 10-unit Visual Analog Scale (VAS) where "0" represents no pain and "10" represents the most severe pain possible. A lower score indicates a reduction in headache intensity

    Measured 3 times during each hemodialysis session (immediately before, 2 hours after start, and at the end of dialysis) over a period of 4 weeks (total of 12 sessions).

Secondary Outcomes (2)

  • State Anxiety Levels measured by State Anxiety Inventory (STAI-S).

    Measured at the 2nd and 4th hours of dialysis sessions throughout the 4-week study period.

  • Trait Anxiety Level (STAI-T)

    At the beginning of the study (baseline) and at the end of the 4th week.

Study Arms (2)

Pure Lavender Oil Inhalation Group

OTHER

Participants assigned to the lavender oil inhalation intervention.

Other: Lavender Oil Inhalation

Control group patients.

OTHER

A total of 32 control group patients (standard hemodialysis care)

Other: Standard Hemodialysis Care

Interventions

Participants receive pure medical lavender oil (Lavandula angustifolia) with a certificate of analysis. During the 2nd hour of the dialysis session, 3 drops of lavender oil are applied to a 6x6 cm gauze pad. Patients are instructed to inhale the scent from a distance of 5 cm for 5 minutes. This procedure is performed 3 times a week for 4 weeks, totaling 12 sessions. The dosage adjustment and application are performed by the researchers.

Also known as: Aromatherapy with Lavender Oil, Lavandula angustifolia inhalation
Pure Lavender Oil Inhalation Group

Participants in the control group receive only routine hemodialysis treatment. No additional aromatherapeutic intervention or inhalation is administered during the study period.

Control group patients.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Those who are 18 years of age and over,
  • Able to understand and communicate in Turkish,
  • Receiving hemodialysis treatment three times a week for at least 3 months,
  • Not pregnant and not planning a pregnancy,
  • Having a pain intensity of 3 or more on the Visual Analog Scale, measured twice,
  • Headache that develops during dialysis,
  • Headache worsening throughout the dialysis session,
  • Headache resolves spontaneously within 72 hours after dialysis ends,
  • No visual or hearing impairment,
  • Individuals who could take painkillers when they had pain were included in the study

You may not qualify if:

  • Those who are allergic to or uncomfortable with the smell of lavender oil,
  • Having any obstacle to smell,
  • Having a history of asthma,
  • Individuals who used other complementary integrative medicine methods during the treatment process were excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Erciyes Univercity

Kayseri, Turkey (Türkiye)

Location

MeSH Terms

Conditions

PainAnxiety Disorders

Interventions

Aromatherapylavender oil

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsMental Disorders

Intervention Hierarchy (Ancestors)

Mind-Body TherapiesComplementary TherapiesTherapeuticsPhytotherapySensory Art TherapiesPsychotherapyBehavioral Disciplines and Activities

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: It was conducted as a randomized controlled study to determine the effect of pure lavender oil applied by inhalation for 5 minutes, 3 times a week, for a month, on the severity of headaches that develop during dialysis and the level of state-trait anxiety in individuals receiving hemodialysis treatment.
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Phd

Study Record Dates

First Submitted

September 22, 2025

First Posted

December 23, 2025

Study Start

December 1, 2018

Primary Completion

January 30, 2019

Study Completion

August 30, 2019

Last Updated

December 23, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will share

Deidentified individual participant data (IPD) will be shared. Supporting documents such as the study protocol and clinical study report will also be available

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
Beginning 6 months after publication of the study results, and will be available for 10 years.
Access Criteria
The data will be available upon request by contacting the corresponding author via email. The requester must sign a data access agreement.

Locations